« Zurück
Startseite /
Tanshinone IIA sulfonate (sodium)

Tanshinone IIA sulfonate (sodium)

ArtNr	HY-N1370-25mg
Hersteller	MedChem Express
CAS-Nr.	69659-80-9
Menge	25 mg
Quantity options	100 mg 10 mMx1 mL 10 mg 25 mg 500 mg 50 mg 5 mg
Kategorie	Oncology Neuroscience Molecular Targets for Neuroscience Aging & Neurological Disorders Neural Signaling Inhibitors & Compound Libraries Small Molecules By Organ Colorectal Cancer Breast Cancer
Typ	Inhibitors
Specific against	other
Purity	99.77
Citations	[1]Xu QQ, et al. Sodium Tanshinone IIA Sulfonate Attenuates Scopolamine-Induced Cognitive Dysfunctions via Improving Cholinergic System. Biomed Res Int. 2016;2016:9852536\|[2]Jiang Q, et al. Sodium tanshinone IIA sulfonate inhibits hypoxia-induced enhancement of SOCE in pulmonary arterial smooth muscle cells via the PKG-PPAR-γ signaling axis. Am J Physiol Cell Physiol. 2016 Jul 1;311(1):C136-49.\|[3]Ouyang DS, et al. Kinetics of cytochrome P450 enzymes for metabolism of sodium tanshinone IIA sulfonate in vitro. Chin Med. 2016 Mar 22;11:11.\|[4]Chen D, et al. Sodium tanshinone IIA sulfonate and its interactions with human CYP450s. Xenobiotica. 2016 Dec;46(12):1085-1092. Epub 2016 Mar 2.\|[5]Lin S, et al. [Sodium tanshinone IIA sulfonate prevents postoperative peritoneal adhesions in rats by enhancing the activity of the peritoneal fibrinolytic system]. Nan Fang Yi Ke Da Xue Xue Bao. 2016 Feb;36(2):260-4.
Smiles	O=S(C1=C(C)C(C(C(C2=C3C=CC4=C2CCCC4(C)C)=O)=O)=C3O1)(O[Na])=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Sodium Tanshinone IIA sulfonate,Tanshinone IIA sodium sulfonate
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Natural Products
Manufacturer - Applications	COVID-19-immunoregulation
Manufacturer - Targets	CRAC Channel
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Molecular Weight	396.39
Product Description	Tanshinone IIA sulfonate (sodium) is a derivative of tanshinone IIA, which acts as an inhibitor of store-operated Ca2+ entry (SOCE), and is used to treat cardiovascular disorders.
Manufacturer - Research Area	Cardiovascular Disease; Cancer
Solubility	DMSO: 62.5 mg/mL (ultrasonic)\|H2O: 2 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway	Membrane Transporter/Ion Channel
Clinical information	Launched

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-N1370-25mg-safety-datasheet.pdf